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It has long been postulated that the mechanism of action of antipsychotics is related to their ability to block dopamine 2 (DA 2 ) receptors (Creese et al. 1976; Carlsson 1978; Farde et al. 1988) . However, since the introduction of the atypical antipsychotics, most notably clozapine, it has become clear that DA 2 receptor blockade alone is insufficient to explain the clinical potency of all antipsychotic drugs (Meltzer 1989; Davis et al. 1991; Lieberman et al. 1998) . Instead, it has been proposed that the mechanism of action of antipsychotics is rooted in their ability to affect both DA and serotonin (5-hydroxytryptamine, 5-HT) systems in the brain or, more specifically, their interaction (Meltzer 1989; Hsiao et al. 1993a; Kahn et al. 1993; Szymanski et al. 1993; Schmidt et al. 1995; Kapur and Remington 1996; Lieberman et al. 1998) . Indeed, DA and 5-HT are functionally (Agren et al. 1986; Risby et al. 1987; Kelland et al. 1990; Roth and Meltzer 1995; Iyer and Bradberry 1996; Lieberman et al. 1998; ) and anatomically (Ternaux et al. 1977; Priestley et al. 1981; Hetey and Drescher 1986; Fibiger and Miller 1987; Törk 1991 ) strongly related and thus may hardly be regarded independently.
One way to examine DA and 5-HT systems in the brain is through measurement of their metabolites in cerebrospinal fluid (CSF) , that is, homovanillic acid (HVA) and 5-hydroxyindole-acetic acid (5-HIAA), respectively. Several studies (Garelis and Sourkes 1973; Weir et al. 1973; Wood 1980; Andersen et al. 1981; Bertilsson et al. 1982; Stanley et al. 1985; Wester et al. 1990 ; cf. Banki and Molnar 1981; Potter and Manji 1993) have demonstrated that concentrations of HVA and 5-HIAA in CSF reliably reflect HVA and 5-HIAA concentrations in the brain. This suggests that CSF HVA and 5-HIAA concentrations reflect central DA and 5-HT turnover and thus can be used to examine the effects of antipsychotic drugs on these two neurotransmitters and their ratio in vivo (Agnati et al. 1995; Silver et al. 1996) .
It has been shown that typical antipsychotics, which predominantly block DA 2 receptors, increase CSF HVA concentrations (Wode-Helgodt et al. 1977; Härnryd et al. 1984; Sharma et al. 1989; Hsiao et al. 1993b; Kahn et al. 1993; Wieselgren and Lindstrom 1998; ) and the HVA/5-HIAA ratio (Wode-Helgodt et al. 1977; Härn-ryd et al. 1984; Hsiao et al. 1993b; Kahn et al. 1993 ) without significantly affecting CSF 5-HIAA concentrations. Interestingly, the increase of the HVA/5-HIAA ratio (Kahn et al. 1993; Wieselgren and Lindstrom 1998) , but not the increase of the HVA concentrations (Sedvall et al. 1974; Kahn et al. 1993; Sharma et al. 1993) , was found to be related to symptomatic improvement after treatment with typical antipsychotics, suggesting that the therapeutic effect of these antipsychotics is associated with changing DA function relative to 5-HT function, rather than changing DA function per se. Studies examining the effects of the atypical antipsychotics on CSF monoamine metabolites in schizophrenia are lacking, except for a few studies investigating clozapine's impact on these metabolites in refractory patients (Banki 1978; Hsiao et al. 1993b; Szymanski et al. 1993; Risch and Lewine 1995) or in childhood onset schizophrenia (Jacobsen et al. 1997) . In these studies, clozapine failed to alter CSF HVA and 5-HIAA concentrations or the HVA/5-HIAA ratio. However, it was reported that patients who respond well to clozapine display lower pretreatment CSF HVA/5-HIAA ratios than patients who do not respond to clozapine (Pickar et al. 1992; Risch and Lewine 1993; Szymanski et al. 1993; Lieberman et al. 1994; Risch and Lewine 1995; ) . This suggests that, again, the DA/5-HT ratio is important with respect to (in this case in predicting) treatment response.
This study examined the effect of the atypical antipsychotic olanzapine on HVA and 5-HIAA concentrations and their ratio in CSF in a non-refractory group of schizophrenic patients. We hypothesized that treatment with olanzapine would alter the HVA/5-HIAA ratio and that this change (or the pretreatment HVA/5-HIAA ratio) would be related to treatment response.
METHODS

Subjects
Twenty-three male schizophrenic patients (mean age ϭ 31.0 years, SD ϭ 8.8; mean duration of illness 80.4 months, SD ϭ 78.3) participated in this study. During the study all patients were treated as inpatients at the University Medical Center in Utrecht. After the study they were all treated as outpatients. Upon entry into the study, patients were evaluated using the Comprehensive Assessment for Symptoms and History (CASH) interview (Andreasen et al. 1992) , and met DSM-IV criteria for schizophrenia paranoid type (n ϭ 15), disorganized type (n ϭ 4), undifferentiated type (n ϭ 1), schizophreniform disorder (n ϭ 1), or schizoaffective disorder (n ϭ 2). The CASH interview was performed by two trained raters who independently determined the diagnosis and afterwards achieved consensus. All patients had normal results for laboratory and physical examinations and were free of alcohol or drug abuse, according to DSM-IV criteria, for at least 3 months. Subjects with medical illness, or who used depot medication within 2 months before the study entry were excluded from participation. Patients were previously treated with typical antipsychotics (n ϭ 6), atypical antipsychotics (n ϭ 5), both typical and atypical antipsychotics (n ϭ 5), or had no prior antipsychotic treatment (n ϭ 7). One patient, who had been previously treated with typical and atypical antipsychotics, had been drug free for 12 years prior to the study. Five patients did not complete the study because they refused further participation (n ϭ 4), or needed corticosteroids to treat a somatic disorder (n ϭ 1). After a complete description of the study, written informed consent was obtained from all subjects prior to participation.
Procedure
Psychopathology, duration of illness, and prior medication history were assessed using the CASH interview and the Positive and Negative Symptom Scale (PANSS; Kay et al. 1987) . Patients who were on antipsychotic medication (n ϭ 15) were withdrawn from it and remained free of antipsychotic medication for at least 2 weeks before the LP (mean duration of the drug-free period was 35 days, SD ϭ 43, median of 16 days). Up to 40 mg/day diazepam equivalents were allowed for insomnia or agitation throughout the study. No other medication was allowed. Following the drug-free period, patients underwent an LP after maintaining bed rest and fasting (except for water) from 23:00 before the procedure. The LP was performed between 09:00 and 10:00 with patients in the lateral decubitus position. Eleven drops (0.5 ml) of CSF were collected into tubes by a standard procedure, gently mixed, transported in dry ice, and stored at Ϫ 70 Њ C until analysis. Within 1 week following the LP, patients were treated with 10 mg olanzapine daily for 6 weeks. During the sixth week of treatment with olanzapine, the LP was repeated. The PANSS was rated, by trained raters, on the day olanzapine was started (baseline) and then weekly during treatment with the antipsychotic. Interrater reliability was r ϭ 0.95. A 20% or greater reduction in total PANSS scores from baseline to week 6 was defined a priori as treatment response, while lack of such a change was defined as treatment nonresponse.
Biochemical Analysis
CSF 5-HIAA and HVA were analyzed by means of liquid chromotography, as desribed previously (Westenberg and Verhoeven 1988) . Briefly, after thawing, 25 L CSF was centrifuged at 1200 g for 2 min, and the supernatant was injected into the liquid chromatograph. Separation was performed on a YMC-pack ODS column (Inacom Instruments, Amsterdam, The Netherlands) using a mobile phase consisting of 0.05 M acetate buffer (pH ϭ 4), 12.5 % methanol, 30 mg/L heptanesulfonic acid, and 100 mg/L EDTA. The components were separated at 40 Њ C and detected with an electrochemical detector (Antec, Amsterdam, The Netherlands) at a potential of 800 mV. The data were analyzed using a Chromeleon Chromatographic Data system. Calibration was achieved by analyzing CSF samples supplemented with known amounts of the compounds of interest. The sensitivity of the method is 1fmol/ L CSF for both compounds and the inter-and intra-coefficients of variations were 6% and 5%, respectively.
Data Analysis
The effects of olanzapine treatment on CSF metabolites were analyzed using paired t tests. Variables used were HVA and 5-HIAA concentrations and the HVA/5-HIAA ratio. To examine the relationship between HVA and 5-HIAA concentrations, before and after treatment with olanzapine, Pearson correlations were performed. Change of symptomatology during treatment with olanzapine was calculated using repeated measures ANOVA on PANSS scores with the factor "Time" (7 levels: baseline, week 1, week 2, week 3, week 4, week 5, and week 6). To correlate HVA and 5-HIAA concentrations, and the HVA/5-HIAA ratio, before and after treatment, with symptoms at that time, partial correlations were used. Pearson correlations were used to examine the relationship between changes in symptomatology ( ⌬ PANSS ϭ PANSS before treatment Ϫ PANSS after treatment ) and changes in HVA concentrations ( ⌬ HVA ϭ HVA before treatment Ϫ HVA after treatment ), 5-HIAA concentrations ( ⌬ 5-HIAA ϭ 5-HIAA before treatment -5-HIAA after treatment ), and the HVA/5-HIAA ratio ( ⌬ HVA/5-HIAA ϭ Data were also examined through multiple regression using a multivariate general linear model with final ratings of the total PANSS, positive, negative, and general symptoms of the PANSS as dependent variable and initial ratings of the corresponding measures, baseline HVA concentrations (or baseline 5-HIAA concentrations or the baseline HVA/5-HIAA ratio), and final HVA concentrations (or final 5-HIAA concentrations or the final HVA/5-HIAA ratio) as covariates. The same analysis was used to predict final ratings of the PANSS (dependent variable) from initial PANSS ratings and initial HVA, 5-HIAA levels and the initial HVA/5-HIAA ratio (covariates).
Pearson correlations were used to examine the relationship between CSF variables and pre-study status of the patients (i.e., age, weight, smoking, illness duration, and prior typical, atypical, or combined antipsychotic treatment).
RESULTS
Olanzapine treatment significantly increased HVA concentrations (t ϭ Ϫ 3.127, df ϭ 1;17, p Ͻ .01) and the HVA/5-HIAA ratio (t ϭ Ϫ 4.704, df ϭ 1;17, p Ͻ .001), but did not affect 5-HIAA concentrations (t ϭ Ϫ .516, df ϭ 1;17, p ϭ .612) ( Table 1) .
HVA and 5-HIAA concentrations were significantly correlated before treatment (r ϭ .824, p Ͻ .001) and after treatment with olanzapine (r ϭ .841, p Ͻ .001).
Patients significantly improved during treatment with olanzapine, as was demonstrated by a decrease in the PANSS score over time (total PANSS score: F ϭ 5.666, df ϭ 6;12, p Ͻ .01; positive symptoms: F ϭ 3.608, df ϭ 6;12, p Ͻ .05; negative symptoms: F ϭ 3.737, df ϭ 6;12, p Ͻ .05; general symptoms: F ϭ 5.101, df ϭ 6;12, p Ͻ .01).
After treatment, negative symptoms of the PANSS were significantly correlated with HVA concentrations (HVA after treatment: r ϭ Ϫ.591, p Ͻ .01) (Figure 1 ), but not with 5-HIAA or the HVA/5-HIAA ratio. No significant correlations were found for negative symptoms with CSF metabolites before treatment with olanzapine. Also no significant correlations were found for positive or general symptoms of the PANSS with the CSF metabolites or their ratio.
Change in PANSS score was not significantly related to change in HVA concentrations (r ϭ Ϫ.070, p ϭ .783) or change in the ratio of HVA/5-HIAA (r ϭ Ϫ.345, p ϭ .161). No differences were found between responders (n ϭ 10) and nonresponders (n ϭ 8) to olanzapine treatment in change in HVA concentrations (t ϭ .013, df ϭ 2;16, p ϭ .990) or in change in the HVA/5-HIAA ratio (t ϭ .150, df ϭ 2;16, p ϭ .882). Pretreatment HVA concentrations, 5-HIAA concentrations, nor the HVA/5-HIAA ratio were significantly related to treatment re- No significant correlations were found between final HVA concentrations, 5-HIAA concentrations or their ratio with final PANSS ratings in a multiple regression (HVA: F ϭ 3.125, df ϭ 3;10, p ϭ .075; 5-HIAA: F ϭ 1.109, df ϭ 3;10, p ϭ .391; HVA/5-HIAA: F ϭ 0.11, df ϭ 3;10, p ϭ .952). Correlations of HVA concentrations, 5-HIAA concentrations or their ratio with total PANSS score, positive, negative, and general symptoms of the PANSS separately also were not significant, except the correlation between final HVA concentration and final negative symptoms of the PANSS (F ϭ 8.727, df ϭ 1;17, p ϭ .012). Final total PANSS score, and final positive, negative, and general symptoms of the PANSS were not significantly predicted from initial HVA concentrations, 5-HIAA concentrations, or their ratio in a multiple regression (HVA: F ϭ 0.654, p ϭ .598, 5-HIAA: F ϭ .312, p ϭ .817, HVA/5-HIAA: F ϭ .076, p ϭ.972).
No significant correlations were found between CSF variables and pre-study status of the patients.
DISCUSSION
Treatment with olanzapine resulted in a significant increase in CSF HVA concentrations and the HVA/ 5-HIAA ratio, while 5-HIAA concentrations were not altered. Olanzapine treatment significantly reduced positive and negative symptoms in these patients. However, no relationship between changes in CSF metabolites and improvement of symptoms was found.
Increases in CSF HVA concentrations and the HVA/ 5-HIAA ratio have also been reported after treatment with typical antipsychotics (Wode-Helgodt et al. 1977; Härnryd et al. 1984; Sharma et al. 1989; Hsiao et al. 1993b; Kahn et al. 1993; Wieselgren and Lindstrom 1998) but not after treatment with the atypical antipsychotic clozapine (Banki 1978; Hsiao et al. 1993b; Szymanski et al. 1993; Risch and Lewine 1995; Jacobsen et al. 1997) . However, in contrast to the studies with typical antipsychotics and the present study, patients in the clozapine studies were treatment refractory (Banki 1978; Hsiao et al. 1993b; Szymanski et al. 1993; Risch and Lewine 1995) or childhood onset (Jacobsen et al. 1997 ) and thus may represent a different group of schizophrenic patients. Hence, it is possible that in a non-treatment refractory sample of schizophrenic patients typical and atypical antipsychotics have the same effect on HVA concentrations and the HVA/5-HIAA ratio in CSF.
The relationship between an increase in the HVA/5-HIAA ratio in CSF and symptom improvement after treatment with typical antipsychotics (Kahn et al. 1993; Wieselgren and Lindstrom 1998) was not replicated in the present study suggesting that, unlike typical antipsychotics, the clinical effect of olanzapine is not related to the increase of dopamine turnover in the brain relative to that of serotonin. Furthermore, the correlation between a low pretreatment CSF HVA/5-HIAA ratio and treatment response to clozapine (Pickar et al. 1992; Risch and Lewine 1993; Szymanski et al. 1993; Lieberman et al. 1994; Risch and Lewine 1995) , once again, may apply only to treatment refractory schizophrenic patients, which could explain why studies with typical antipsychotics, and the present study with olanzapine (all conducted in non-refractory patients), found no significant correlation between the pretreatment HVA/ 5-HIAA ratio and symptom improvement. Moreover, different procedures used in the clozapine studies (i.e., duration of treatment, method of analysis, criteria of response) make it difficult to compare these studies with the present findings.
There are several complications in interpreting CSF monoamine metabolite measurements (Amin et al. 1992; Lieberman and Koreen 1993; Potter and Manji 1993) . For example, acidic metabolites are transported across the brain-blood barrier by a probenecid sensitive organic anion transport system in rat brain (Westerlink and Kikkert 1986) . Olanzapine (like haloperidol) may inhibit this system resulting in an increase of metabolites. However, in our study, only HVA concentrations increased while 5-HIAA concentrations were unchanged, and HVA and 5-HIAA remained strongly related. This suggests that a change in clearance of metabolites by a common acid transport mechanism out of CSF (which would have resulted in an increase of both HVA and 5-HIAA) could not explain the increased HVA concentrations, as was supported by some (Agren et al. 1986; Jibson et al. 1990 ). Other factors play a role in monoamine metabolite concentrations in CSF like age (Asberg 1994 ), smoking (Geracioti et al. 1999 , stress (Hill et al. 1999) , and body weight (Nordin et al. 1995) , which could have influenced our data. However, we found no significant differences between smokers and non-smokers and no significant correlations between age or body weight and CSF monoamine metabolites.
Apart from these considerations, it has been suggested that CSF HVA and 5-HIAA concentrations do not reflect dopamine and serotonin turnover in the whole brain but merely in specific brain regions (i.e., frontal and prefrontal cortex or striatum) (Stanley et al. 1985; Agren et al. 1986; van Kammen et al. 1986; Doran et al. 1987; Elsworth et al. 1987; Wester et al. 1990 ). It could therefore be possible that the clinical efficacy of olanzapine is (partially) related to its effect on dopamine and serotonin receptors in brain regions that do not contribute to the monoamine metabolites in CSF.
Despite the serotonin antagonistic property of olanzapine (Moore et al. 1997; Bymaster et al. 1999) , no sig-nificant alterations of CSF 5-HIAA concentrations were found in the present study. Interestingly, similar findings were obtained when clozapine, also a potent 5-HT antagonist (Kahn et al. 1994a) , was used, suggesting that CSF 5-HIAA concentrations may not be a potent marker for central 5-HT turnover, as has indeed been proposed (Eklundh et al. 1996) . Moreover, because it is shown that the selective serotonin antagonist, ritanserin, does not alter CSF 5-HIAA concentrations (Wiesel et al. 1994) , it may be argued that CSF 5-HIAA concentrations are less suitable to measure the serotonin antagonistic effects of antipsychotics. Thus, treatment response to atypical antipsychotics may not be investigated properly through measurement of CSF HVA and 5-HIAA concentrations because the clinical potency of these antipsychotics appears, in part, to be the result of the antagonistic effect on serotonin receptors (Moore et al. 1994; Lieberman et al. 1998) . Alternatively, other neurotransmitter systems, such as the norepinephrine or glutamate system, are affected by treatment with olanzapine (Moore et al. 1997; Bymaster et al. 1999) , which possibly contributes to olanzapine's clinical efficacy. However, conclusions about the relationship between CSF metabolites and response to olanzapine must be drawn with caution because of the small number of patients in this study.
The negative correlation between HVA concentrations and the negative symptoms of the PANSS after treatment with olanzapine, replicates previous CSF studies in which it was suggested that decreased dopamine turnover in (the frontal cortex of) the brain is associated with negative symptoms of schizophrenia (Lindstrom 1985; Weinberger et al. 1988; Kahn et al. 1994b ). Our findings therefore strengthen the presumption that DA plays a role in the negative symptom complex of schizophrenia (Meltzer 1989; Davis et al. 1991; Duinkerke et al. 1993; Szymanski et al. 1993) .
To conclude, this study found that, although treatment with the atypical antipsychotic olanzapine increased CSF HVA concentrations and the HVA/ 5-HIAA ratio, this effect was not related to treatment response. This suggests that, in a non-refractory sample of schizophrenic patients, the clinical potency of olanzapine may result from its effect on brain regions and/or neurotransmitter systems other than those represented by CSF HVA and 5-HIAA concentrations or their ratio alone. The negative correlation between HVA concentrations and negative symptoms of the PANSS suggests that decreased DA turnover is related to the negative symptom complex of schizophrenia. 
